How to create value with constrained budgets in oncological care? A narrative review

References

• Integraal Kankercentrum Nederland (IKNL). Overleving van kankerpatiënten vijf jaar na diagnose stijgt met ongeveer 1% per jaar. 2020. https://www.iknl.nl/nieuws/2020/overleving-van-kankerpatienten-stijgt-met-ongeveer
   Google Scholar
• World Health Organization (WHO). Cancer tomorrow. A tool that predicts the future cancer incidence and mortality burden worldwide from the current estimates in 2020 up until 2040. 2020. https://gco.iarc.fr/tomorrow/
   Google Scholar
• Kahlon N, Doddi S, Yousif R, et al. Melanoma treatments and mortality rate trends in the US, 1975 to 2019. JAMA Netw Open. 2022 Dec 1;5(12):e2245269. doi: 10.1001/jamanetworkopen.2022.45269
   PubMed Web of Science ®Google Scholar
• Hemminki K, Hemminki J, Försti A, et al. Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J. 2022 Nov 7;12(11):150. doi: 10.1038/s41408-022-00728-z
   PubMed Web of Science ®Google Scholar
• Cliff B. The evolution of patient-centered care. J Healthc Manag. 2012 Mar;57(2):86–88. doi: 10.1097/00115514-201203000-00003
   PubMed Web of Science ®Google Scholar
• Ekman I, Ebrahimi Z, Olaya Contreras P. Person-centred care: looking back, looking forward. Eur J Cardiovasc Nurs. 2021 Apr 13;20(2):93–95.
   PubMed Web of Science ®Google Scholar
• Ekman I, Swedberg K, Taft C, et al. Person-centered care–ready for prime time. Eur J Cardiovasc Nurs. 2011 Dec;10:248–251.
   PubMed Web of Science ®Google Scholar
• Rawson JV, Moretz J. Patient- and family-centered care: a primer. J Am Coll Radiol. 2016 Dec;13(12):1544–1549. doi: 10.1016/j.jacr.2016.09.003
   PubMed Web of Science ®Google Scholar
• IQVIA Institute for Human Data Science. Global Oncology Trends 2022: outlook to 2026. 2022
   Google Scholar
• Vrinzen CEJ, Bloemendal HJ, Stuart E, et al. Cancer treatments touch a wide range of values that count for patients and other stakeholders: what are the implications for decision-making? Cancer Med. 2023 Mar;12(5):6105–6116. doi: 10.1002/cam4.5336
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review 2020-2023. Value Assessment Framework. 2020
   Google Scholar
• EUnetHTA. Joint action on HTA 2012-2015, HTA core model version 3.0 2016
   Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of clinical oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934. doi: 10.1200/JCO.2016.68.2518
   PubMed Web of Science ®Google Scholar
• Cherny NI, Sullivan R, Dafni U, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for medical oncology magnitude of clinical benefit scale (ESMO-MCBS). Ann Oncol. 2015 Aug;26(8):1547–1573. doi: 10.1093/annonc/mdv249
   PubMed Web of Science ®Google Scholar
• Zorginstituut Nederland (Dutch National Healthcare Institute). Pakketadvies sluisgeneesmiddel sacituzumab govitecan (Trodelvy) voor de behandeling van inoperabele of uitgezaaide borstkanker. 2023.
   Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5–21. doi: 10.1093/bmb/ldq033
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Doshi JA, Garrison LP Jr., et al. Defining elements of value in health care-A health economics approach: an ISPOR Special Task Force Report [3]. Value Health. 2018 Feb;21:131–139.
   PubMed Web of Science ®Google Scholar
• Lakdawalla DN, Romley JA, Sanchez Y, et al. How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapies. Health Aff. 2012 Apr;31(4):676–682. doi: 10.1377/hlthaff.2011.1300
   PubMed Web of Science ®Google Scholar
• Lin X-J, Lin IM, Fan S-Y. Methodological issues in measuring health-related quality of life. Tzu Chi Med J. 2013 Mar;25(1):8–12. doi: 10.1016/j.tcmj.2012.09.002
   Google Scholar
• Caro JJ, Brazier JE, Karnon J, et al. Determining value in health technology assessment: stay the course or tack away? PharmacoEconomics. 2019 Mar;37(3):293–299. doi: 10.1007/s40273-018-0742-2
   PubMed Web of Science ®Google Scholar
• Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018 Jan;19(1):123–152. doi: 10.1007/s10198-017-0871-0
   PubMed Web of Science ®Google Scholar
• Cheema PK, Gavura S, Migus M, et al. International variability in the reimbursement of cancer drugs by publically funded drug programs. Curr Oncol. 2012 Jun;19(3):e165–76. doi: 10.3747/co.19.946
   PubMed Web of Science ®Google Scholar
• de Ligt KM, van Egdom LSE, Koppert LB, et al. Opportunities for personalised follow-up care among patients with breast cancer: a scoping review to identify preference-sensitive decisions. Eur J Cancer Care (Engl). 2019 May;28:e13092.
   PubMed Web of Science ®Google Scholar
• Meijers MC, Noordman J, Spreeuwenberg P, et al. Shared decision-making in general practice: an observational study comparing 2007 with 2015. Fam Pract. 2019 May 23;36:357–364.
   PubMed Web of Science ®Google Scholar
• Spinnewijn L, Aarts J, Verschuur S, et al. Knowing what the patient wants: a hospital ethnography studying physician culture in shared decision making in the Netherlands. BMJ Open. 2020 Mar 18;10(3):e032921. doi: 10.1136/bmjopen-2019-032921
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Yang L. Personalising cancer medicine with prognostic markers. EBioMedicine. 2021 Oct;72:103577. doi: 10.1016/j.ebiom.2021.103577
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Carter CA, Giaccone G. The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer. Curr Opin Invest Drugs. 2009 Dec;10(12):1305–1314.
   PubMedGoogle Scholar
• Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol. 2008 Aug;8(4):413–418. doi: 10.1016/j.coph.2008.06.006
   PubMed Web of Science ®Google Scholar
• Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022 Jun 16;386(24):2261–2272. doi: 10.1056/NEJMoa2200075
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Gondos A, Saldana D, et al. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United states: a contemporary clinical practice patterns study. Lung Cancer. 2022 May;167:41–48. doi: 10.1016/j.lungcan.2022.01.021
   PubMed Web of Science ®Google Scholar
• Colomer R, Mondejar R, Romero-Laorden N, et al. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine. 2020 Aug;25:100487. doi: 10.1016/j.eclinm.2020.100487
   PubMedGoogle Scholar
• Tan O, Shrestha R, Cunich M, et al. Application of next-generation sequencing to improve cancer management: a review of the clinical effectiveness and cost-effectiveness. Clin Genet. 2018;93(3):533–544. doi: 10.1111/cge.13199
   PubMed Web of Science ®Google Scholar
• Schwarze K, Buchanan J, Taylor JC, et al. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018 Oct;20(10):1122–1130. doi: 10.1038/gim.2017.247
   PubMed Web of Science ®Google Scholar
• Simons MJHG, Uyl-de Groot CA, Retèl VP, et al. Cost-effectiveness and budget impact of future developments with whole-genome sequencing for patients with lung cancer. Value Health. 2023 Jan;26(1):71–80. doi: 10.1016/j.jval.2022.07.006
   PubMed Web of Science ®Google Scholar
• Liu A, Vicenzi P, Sharma I, et al. Molecular tumor boards: the next step towards precision therapy in cancer care. Hematol Rep. 2023;15(2):244–255. doi: 10.3390/hematolrep15020025
   PubMed Web of Science ®Google Scholar
• Tamborero D, Dienstmann R, Rachid MH, et al. The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer. 2022 Feb;3:251–261.
   PubMedGoogle Scholar
• Willemsen AECAB, Krausz S, Ligtenberg MJL, et al. Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations. Br J Cancer. 2019 Jul;121:34–36.
   PubMed Web of Science ®Google Scholar
• Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, et al. Differences in trial and real-world populations in the Dutch castration-resistant prostate cancer registry. Eur Urol Focus. 2018 Sep;4(5):694–701. doi: 10.1016/j.euf.2016.09.008
   PubMedGoogle Scholar
• Giordano SH. Comparative effectiveness research in cancer with observational data. Am Soc Clin Oncol Educ Book. 2015;35:e330–5. doi: 10.14694/EdBook_AM.2015.35.e330
   PubMedGoogle Scholar
• Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011 Sep;12(10):933–980. doi: 10.1016/S1470-2045(11)70141-3
   PubMed Web of Science ®Google Scholar
• Gonçalves FR, Santos S, Silva C, et al. Risk-sharing agreements, present and future. Ecancermedicalscience. 2018;12:823.
   PubMed Web of Science ®Google Scholar
• Zeverijn LJ, van Waalwijk van Doorn-Khosrovani SB, van Roy AAMGP, et al. Harmonising patient-access programmes: the Dutch drug access protocol platform. Lancet Oncol. 2022;23(2):198–201. doi: 10.1016/S1470-2045(21)00707-5
   PubMed Web of Science ®Google Scholar
• Boddaert MS, Pereira C, Adema J, et al. Inappropriate end-of-life cancer care in a generalist and specialist palliative care model: a nationwide retrospective population-based observational study. BMJ Support Palliat Care. 2022 May;12(e1):e137–45. doi: 10.1136/bmjspcare-2020-002302
   PubMed Web of Science ®Google Scholar
• Zhang B, Wright AA, Huskamp HA, et al. Health care costs in the last week of life: associations with end-of-life conversations. Arch Intern Med. 2009 Mar 9;169(5):480–488. doi: 10.1001/archinternmed.2008.587
   PubMedGoogle Scholar
• Armes J, Crowe M, Colbourne L, et al. Patients’ supportive care needs beyond the end of cancer treatment: a prospective, longitudinal survey. J Clin Oncol. 2009 Dec 20;27(36):6172–6179. doi: 10.1200/JCO.2009.22.5151
   PubMed Web of Science ®Google Scholar
• Berman R, Davies A, Cooksley T, et al. Supportive care: an indispensable component of modern oncology. Clin Oncol. 2020 Nov;32(11):781–788. doi: 10.1016/j.clon.2020.07.020
   PubMed Web of Science ®Google Scholar
• Sender A, Friedrich M, Leuteritz K, et al. Unmet supportive care needs in young adult cancer patients: associations and changes over time. Results from the AYA-Leipzig study. J Cancer Survivorship. 2019 Aug;13(4):611–619. doi: 10.1007/s11764-019-00780-y
   PubMed Web of Science ®Google Scholar
• Smith AW, Parsons HM, Kent EE, et al. Unmet support service needs and health-related quality of life among adolescents and young adults with cancer: the AYA HOPE study. Front Oncol. 2013;3:75.
   PubMedGoogle Scholar
• Chan B, Sim H-W, Zimmermann C, et al. Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients. J Clin Oncol. 2016;34(26_suppl):21. doi: 10.1200/jco.2016.34.26_suppl.21
   Web of Science ®Google Scholar
• Levoy K, Salani DA, Buck H. A systematic review and gap analysis of advance care planning intervention components and outcomes among cancer patients using the transtheoretical model of health behavior change. Journal Of Pain And Symptom Management. 2019 Jan;57(1):118–139. doi: 10.1016/j.jpainsymman.2018.10.502
   PubMed Web of Science ®Google Scholar
• Grover H, King W, Bhattarai N, et al. Systematic review of the cost-effectiveness of screening for lung cancer with low dose computed tomography. Lung Cancer. 2022 Aug;170:20–33. doi: 10.1016/j.lungcan.2022.05.005
   PubMed Web of Science ®Google Scholar
• Khan SA, Hernandez-Villafuerte KV, Muchadeyi MT, et al. Cost-effectiveness of risk-based breast cancer screening: a systematic review. Int J Cancer. 2021;149:790–810.
   Web of Science ®Google Scholar
• Mühlberger N, Sroczynski G, Gogollari A, et al. Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. Eur J Health Econ. 2021 Nov;22(8):1311–1344. doi: 10.1007/s10198-021-01338-5
   PubMed Web of Science ®Google Scholar
• Alonso-Belmonte C, Montero-Vilchez T, Arias-Santiago S, et al. Situación actual de la prevención del cáncer de piel: una revisión sistemática. Actas Dermo-Sifiliográficas. 2022 Sep;113(8):781–791. doi: 10.1016/j.ad.2022.04.015
   PubMedGoogle Scholar
• McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical activity in cancer prevention and survival: a systematic review. Med Sci Sports Exercise. 2019 Jun;51(6):1252–1261. doi: 10.1249/MSS.0000000000001937
   PubMed Web of Science ®Google Scholar
• Zhang YB, Pan XF, Chen J, et al. Combined lifestyle factors, incident cancer, and cancer mortality: a systematic review and meta-analysis of prospective cohort studies. Br J Cancer. 2020 Mar;122(7):1085–. doi: 10.1038/s41416-020-0741-x
   PubMed Web of Science ®Google Scholar
• Cadham CJ, Cao P, Jayasekera J, et al. Cost-effectiveness of smoking cessation interventions in the lung cancer screening setting: a simulation study. J Natl Cancer Inst. 2021 Aug 2;11:1065–1073.
   Google Scholar
• Leão T, Kunst AE, Perelman J. Cost-effectiveness of tobacco control policies and programmes targeting adolescents: a systematic review. Eur J Public Health. 2018 Feb 1;28(1):39–43. doi: 10.1093/eurpub/ckx215
   PubMed Web of Science ®Google Scholar
• Chang WH, Katsoulis M, Tan YY, et al. Late effects of cancer in children, teenagers and young adults: population-based study on the burden of 183 conditions, in-patient and critical care admissions and years of life lost. Lancet Reg Health Eur. 2022 Jan;12:100248.
   PubMedGoogle Scholar
• Reulen RC, Winter DL, Frobisher C, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA. 2010 Jul 14;304(2):172–179. doi: 10.1001/jama.2010.923
   PubMed Web of Science ®Google Scholar
• de Rooij BH, Park ER, Perez GK, et al. Cluster analysis demonstrates the need to individualize care for cancer survivors. Oncology. 2018 Dec;23(12):1474–1481. doi: 10.1634/theoncologist.2017-0558
   Google Scholar
• de Rooij BH, Ezendam NPM, Vos MC, et al. Patients’ information coping styles influence the benefit of a survivorship care plan in the ROGY care trial: new insights for tailored delivery. Cancer. 2019 Mar 1;125:788–797.
   PubMed Web of Science ®Google Scholar
• Huo YR, Phan K, Morris DL, et al. Systematic review and a meta-analysis of hospital and surgeon volume/outcome relationships in colorectal cancer surgery. J Gastrointest Oncol. 2017 Jun;8(3):534–546. doi: 10.21037/jgo.2017.01.25
   PubMed Web of Science ®Google Scholar
• Raphael MJ, Siemens R, Peng Y, et al. Volume of systemic cancer therapy delivery and outcomes of patients with solid tumors: a systematic review and methodologic evaluation of the literature. J Cancer Policy. 2020 Mar;23:100215. doi: 10.1016/j.jcpo.2020.100215
   Web of Science ®Google Scholar
• Trinh QD, Bjartell A, Freedland SJ, et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol. 2013 Nov;64:786–798.
   PubMed Web of Science ®Google Scholar
• Blay JY, Casali P, Bouvier C, et al. European reference network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN. ESMO Open. 2021 Aug;6(4):100174. doi: 10.1016/j.esmoop.2021.100174
   PubMed Web of Science ®Google Scholar
• Kesson EM, Allardice GM, George WD, et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women. BMJ. 2012 Apr 26;344(apr26 1):e2718. doi: 10.1136/bmj.e2718
   PubMed Web of Science ®Google Scholar
• Munro A, Brown M, Niblock P, et al. Do multidisciplinary team (MDT) processes influence survival in patients with colorectal cancer? A population-based experience. BMC Cancer. 2015 Oct 13;15(1):686. doi: 10.1186/s12885-015-1683-1
   PubMedGoogle Scholar
• Kerkhofs TMA, Verhoeven RHA, Bonjer HJ, et al. Surgery for adrenocortical carcinoma in the Netherlands: analysis of the national cancer registry data. Eur J Endocrinol. 2013 Jul 01;169:83.
   PubMed Web of Science ®Google Scholar
• Schutte HW, van den Broek GB, Steens SCA, et al. Impact of optimizing diagnostic workup and reducing the time to treatment in head and neck cancer. Cancer. 2020 Sep 1;126(17):3982–3990. doi: 10.1002/cncr.33037
   PubMed Web of Science ®Google Scholar
• van Hoeve J, de Munck L, Otter R, et al. Quality improvement by implementing an integrated oncological care pathway for breast cancer patients. Breast. 2014 Aug;23(4):364–370. doi: 10.1016/j.breast.2014.01.008
   PubMed Web of Science ®Google Scholar
• McCullough AL, Scotland TR, Dundas SR, et al. The impact of a managed clinical network on referral patterns of sarcoma patients in Grampian. Scott Med J. 2014 May;59(2):108–113. doi: 10.1177/0036933014529241
   PubMed Web of Science ®Google Scholar
• Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid tumours:a nationwide survey of labelled reference centre networks in France. Eur J Cancer. 2016 May;58:90–96. doi: 10.1016/j.ejca.2016.02.008
   PubMed Web of Science ®Google Scholar
• Steen MW, van Vliet C, Festen S, et al. Regional oncology network between pancreatic centers safeguards waiting times for pancreatoduodenectomy. Updates Surg. 2019 Dec;71(4):645–651. doi: 10.1007/s13304-019-00677-6
   PubMed Web of Science ®Google Scholar
• van Altena AM, van den Akker PA, de Hullu JA, et al. Efficacy of a regional network for ovarian cancer care. Obstet Gynecol. 2013 Sep;122(3):668–675. doi: 10.1097/AOG.0b013e3182a054ee
   PubMed Web of Science ®Google Scholar
• Wind A, Oberst S, Westerhuis W, et al. Evaluating comprehensive cancer networks; a review of standards and evaluation methods for care networks to inform a comparison with the OECI comprehensive cancer network standards. Acta Oncol. 2023 Jan;62(1):15–24. doi: 10.1080/0284186X.2023.2170275
   PubMed Web of Science ®Google Scholar
• Vrinzen CEJ, Delfgou L, Stadhouders N, et al. A systematic review and multilevel regression analysis reveals the comorbidity prevalence in cancer. Cancer Res. 2023 Apr 4;83(7):1147–1157. doi: 10.1158/0008-5472.CAN-22-1336
   PubMed Web of Science ®Google Scholar
• Cortaredona S, Ventelou B. The extra cost of comorbidity: multiple illnesses and the economic burden of non-communicable diseases. BMC Med. 2017 Dec 8;15(1):216. doi: 10.1186/s12916-017-0978-2
   PubMedGoogle Scholar
• Genther DJ, Gourin CG. Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery in the elderly. Head Neck. 2015 May;37(5):685–693. doi: 10.1002/hed.23651
   PubMed Web of Science ®Google Scholar
• Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. CA Cancer J Clin. 2016 Jul;66(4):337–350. doi: 10.3322/caac.21342
   PubMed Web of Science ®Google Scholar
• Søgaard M, Thomsen RW, Bossen KS, et al. The impact of comorbidity on cancer survival: a review. Clin Epidemiol. 2013 Nov 1;5:3–29.
   PubMedGoogle Scholar
• Nolte E, Morris M, Landon S, et al. Exploring the link between cancer policies and cancer survival: a comparison of international cancer benchmarking partnership countries. Lancet Oncol. 2022 Nov;23(11):e502–14. doi: 10.1016/S1470-2045(22)00450-8
   PubMed Web of Science ®Google Scholar
• Plsek PE, Greenhalgh T. Complexity science: the challenge of complexity in health care. BMJ. 2001 Sep 15;323(7313):625–628.
   PubMed Web of Science ®Google Scholar
• Sweeney SM, Hamadeh HK, Abrams N, et al. Challenges to using big data in cancer. Cancer Res. 2023;83(8):1175–1182. doi: 10.1158/0008-5472.CAN-22-1274
   PubMed Web of Science ®Google Scholar